Bronchiectasis (non-CF)

Meet the patient

A 54-year-old woman arrives in clinic with a cough she has had for twelve years, bringing up a cup of yellow-green sputum every morning, worse in winter. She has had four courses of antibiotics in the last year for "chest infections". On examination she has coarse crackles at both bases, finger clubbing, and an old TB scar on the chest X-ray. Spirometry shows a mildly obstructive pattern that does not fully reverse.^[1][11]

The registrar writes "COPD exacerbation" — and that is the trap the whole topic turns on. Three diseases cause a chronic productive cough with clubbing and crackles, and only one is permanently dilated bronchi: COPD (smoker, no dilation on HRCT), chronic bronchitis (cough for 3 months in 2 successive years, no dilation), and bronchiectasis (daily mucopurulent sputum for years, coarse crackles, clubbing, and the signet-ring sign on HRCT). One test settles it, and that test is the high-resolution CT.^[1][12]

Why the airways dilate and stay dilated — Cole's vicious circle

Bronchiectasis is the permanent, abnormal dilation of bronchi whose elastic and muscular wall has been eaten away — and the dilation is self-sustaining. Once the wall weakens, the dilated bronchus clears secretions even more poorly, the pooled mucus becomes infected, neutrophils arrive, and their elastase destroys more wall. That is Cole's vicious circle, and it is the single mechanism every answer must name.^[6][1]

Etymology for viva gold: bronchiectasis is Greek — bronkhos, windpipe, plus ektasis, dilation. Laennec coined the term in the early 19th century (the same Laennec of the stethoscope), and Lynne Reid's 1950 morphological classification — cylindrical, varicose, cystic — is still how radiologists report it today. Before HRCT, diagnosis meant bronchography (instilling contrast into the bronchial tree) and was often missed; the disease was once far commoner than the textbooks admitted.^[1]

Treat it as a syndrome of four treatable traits, not a single disease: infection, inflammation, impaired mucociliary clearance, and structural airway damage. Two questions decide every case — why are the bronchi dilated? (find the cause; about a third remain idiopathic, but ABPA, immunodeficiency, post-TB and primary ciliary dyskinesia are all treatable) and how bad is it? (stratify with the BSI or FACED score to decide who needs long-term suppressive therapy).^[1]

Separate it sharply from its three cough-and-sputum cousins, because the HRCT is the arbiter: chronic bronchitis is a daily productive cough for at least 3 months in 2 successive years with no HRCT dilation; COPD is small-airway and parenchymal disease with fixed airflow obstruction and no dilation; asthma is variable, eosinophilic, and reversible. Daily mucopurulent sputum for years plus coarse crackles and clubbing is bronchiectasis until the HRCT proves otherwise.^[1]

Everyone forgets the five-question first-visit checklist. At the first consultation ask: (1) is the diagnosis confirmed on HRCT? (2) what is the extent and severity (BSI/FACED)? (3) what is the cause, and have I excluded the treatable ones? (4) what is the microbiology — sputum including NTM culture? (5) what is the functional status and comorbidity? Answer all five and the patient lands in the right management lane.^[1]

^[1]

Three axes — morphology, distribution, aetiology

Classify bronchiectasis three ways because each axis changes a decision: morphology sets prognosis, distribution predicts the cause, and aetiology sets the treatment. A regional registrar reading an HRCT must answer all three before phoning the consultant.^[1]

By morphology (Reid's classification, read straight off the HRCT):^[1]

What juniors miss: morphology is a prognosis dial, not a label. Cylindrical disease can occasionally regress if you treat the cause early — pull out the foreign body, start immunoglobulin replacement — but cystic change is irreversible, full stop. Mixed varicose-and-cystic areas in the same lung predict worse outcomes, so name them on the report.^[1]

By distribution — and the one question that drives the work-up: why that one lobe?^[1]

• Localised (single lobe/segment) — almost always post-infective (TB, pertussis, measles, adenovirus) or post-obstructive (foreign body, endobronchial tumour, node compression). A single destroyed lobe earns a bronchoscopy to exclude obstruction before you call it post-infective.
• Diffuse (bilateral, multi-lobar) — reach for a systemic cause: immunodeficiency, PCD, CF, ABPA, rheumatoid arthritis, aspiration, or idiopathic.^[1]

Distribution predicts cause — memorise the lobe-to-cause map, it is pure exam gold:^[1]

^[1]

Etymology for viva gold — the Lady Windermere syndrome: M. avium complex loves the right middle lobe and lingula of elderly, thin women who suppress their cough out of politeness. It is named after the fastidious spinster in Oscar Wilde's Lady Windermere's Fan — the very picture of a lady who would never cough in public. Traction bronchiectasis is the exception in the table: the airway is pulled open by surrounding fibrosis in ILD, not destroyed by infection — different mechanism, different management.^[1]

By aetiology — find a treatable cause in every patient, because the cause changes both management and prognosis; the structured aetiology work-up follows below.^[1]

How common, who, and why the airway fails

Bronchiectasis is far commoner than the textbooks once admitted — routine thin-section CT unmasked a disease that bronchography had been missing for decades. UK and US data put adult prevalence near 0.5–1.0 percent, climbing past 5 percent in the over-75s, with a female preponderance in adults (possibly smaller airway calibre and delayed diagnosis). The burden tilts hard toward South Asia, where post-tuberculous and childhood-infection disease dominate the clinics.^[1][11]

The exposures juniors forget to ask about. Infection and host defence dominate the causes, but four environmental triggers earn a place in the history: biomass-fuel smoke (impairs mucociliary clearance across low-income settings), occupational dusts and fumes — silica, coal, cotton — which lay down chronic bronchitis alongside bronchiectasis, aspiration from alcohol, neurological disease, or reflux (chronically under-recognised), and childhood passive smoke exposure, which primes post-infectious bronchiectasis. ABPA is the odd one out — both a cause and a consequence of central bronchiectasis.^[1]

The numbers a viva candidate reproduces without pause:^[1]

^[1]

Aetiology by category — the structured list the examiner wants, grouped so you can recall it under pressure:^[1]

Interpreting the work-up — who gets which test. A systematic work-up is the only protection against missing a treatable cause. Every adult gets immunoglobulins, total IgE with Aspergillus-specific IgE/IgG, alpha-1-antitrypsin, and sputum including NTM culture. Selected patients earn extra tests: CFTR sweat chloride or genetics for the young, upper-lobe, infertile male, or anyone growing Staph aureus or with pancreatic disease; ciliary studies for neonatal respiratory distress, chronic rhinosinusitis, otitis, situs inversus, or infertility. Add a rheumatology screen when joints, skin, or autoimmunity appear, HIV testing by risk, and specific vaccine antibody responses (pneumococcal challenge) to catch functional antibody deficiency hiding behind normal total immunoglobulins.^[1]

The named rarities examiners love to spring — each is a one-line association:^[1]

• Alpha-1-antitrypsin deficiency — causes lower-zone panacinar emphysema in smokers, but can also be associated with bronchiectasis. Check serum alpha-1-antitrypsin level and phenotype/genotype (PiZZ, PiSZ, null alleles). Augmentation therapy is for emphysema, not bronchiectasis per se.
• Young syndrome — obstructive azoospermia and bronchiectasis; historically linked to mercury exposure but now considered a form of obstructive azoospermia with associated sinopulmonary disease. It is a rare cause but a classic named association.
• Yellow nail syndrome — triad of yellow nails, lymphedema, and pleural effusion, often with bronchiectasis. Lymphatic dysfunction is thought to underlie the lung and nail findings.
• Marfan syndrome and Ehlers-Danlos syndrome — connective-tissue defects may predispose to bronchial wall weakness and bronchiectasis.
• Inflammatory bowel disease — both Crohn's disease and ulcerative colitis are associated with bronchiectasis, sometimes preceding bowel diagnosis.

^[1]

Two organisms decide the trajectory: Haemophilus influenzae early, Pseudomonas aeruginosa when it turns severe. H. influenzae is the commonest organism overall in non-CF bronchiectasis, dominating early and mild disease. Pseudomonas aeruginosa is the severity organism — it colonises worse disease, accelerates FEV1 decline, doubles exacerbation frequency, drives hospitalisation, and worsens quality of life and mortality. S. pneumoniae and Moraxella catarrhalis are common early colonisers; Staphylococcus aureus should make you reach for CF or ABPA (especially in children). Non-tuberculous mycobacteria — M. avium complex, M. abscessus — co-exist in roughly 8–10 percent and demand a specific work-up of multiple positive cultures before any treatment.^[1][2]

Cole's circle in full — neutrophil elastase is the villain

Every bronchiectasis answer hangs on one mechanism: Cole's vicious circle, and the four steps that close it. Peter Cole published the hypothesis in 1986, and it still frames the disease — learn the four steps in order, because each step is also the target of one of your treatments.^[6]

1. An initial insult (severe infection such as pertussis or TB, obstruction, or impaired host defence) impairs mucociliary clearance.
2. Retained secretions become infected with bacterial pathogens (H. influenzae, Pseudomonas, S. pneumoniae).
3. Infection triggers neutrophilic inflammation — neutrophils and macrophages release elastase, IL-8, TNF-alpha, MMP-8/9 and reactive oxygen species.
4. Proteases destroy the elastin and muscularis of the bronchial wall; the weakened wall dilates under cough pressure, and the dilated bronchus clears secretions even more poorly — completing the circle.

^[1]

Why neutrophil elastase is the central villain: neutrophil elastase is a serine protease that (i) degrades elastin in the bronchial wall, (ii) stimulates goblet-cell hyperplasia and mucin (MUC5AC) secretion, (iii) slows ciliary beat frequency and strips ciliated epithelium, and (iv) inactivates complement and immunoglobulins and cleaves immune receptors — directly deepening the cycle. Sputum elastase activity correlates with exacerbation frequency and FEV1 decline.^[6][2]

Every bedside sign traces back to a dilated, damaged bronchus — read the mechanism, not the sign:^[1]

• Pooled secretions → daily mucopurulent sputum and coarse crackles (often positional).
• Disruption of airway smooth muscle and wall oedema → wheeze and airflow obstruction (obstructive PFTs, not reversible to normal).
• Hypertrophy and proliferation of bronchial arteries under chronic inflammatory drive → haemoptysis, occasionally massive.
• Ventilation-perfusion mismatch and shunt across poorly ventilated but perfused dilated segments → hypoxaemia; in advanced disease, alveolar hypoventilation → type-2 respiratory failure and cor pulmonale.
• Chronic systemic inflammation → weight loss, anaemia of chronic disease, and secondary (AA) amyloidosis (which can cause nephrotic-range proteinuria).

^[1]

Bronchiectasis is not only large-airway disease — the small airways are in on it too. The tree-in-bud pattern on HRCT is mucus and pus sitting in centrilobular bronchioles, and small-airway obstruction plus mucus plugging drive air trapping, ventilation–perfusion mismatch, and exercise limitation. Add expiratory HRCT cuts when air trapping is suspected — it shows what inspiratory images hide.^[1]

The role of autoimmunity and systemic inflammation. In rheumatoid arthritis or IBD-associated bronchiectasis, systemic immune dysregulation feeds airway inflammation independent of infection — these patients often have diffuse, lower-lobe disease and respond better to immunomodulation of the underlying condition than to repeated antibiotics alone.^[1]

Why bronchiectasis develops — the three prerequisite concepts:

^[1]

1. An initial insult damages mucociliary clearance. This may be an infection (pertussis, measles, adenovirus, severe pneumonia, TB), an obstruction (foreign body, tumour, lymph-node compression), or a host-defence defect (CVID, PCD, CF).
2. A protease–antiprotease imbalance favours tissue destruction. Neutrophil elastase overwhelms endogenous inhibitors such as alpha-1-antitrypsin and secretory leucoprotease inhibitor, leading to unchecked elastolysis.
3. Structural wall damage becomes self-perpetuating. Once dilation occurs, clearance worsens, infection persists, and the cycle continues even if the original insult is removed. This is why bronchiectasis is usually irreversible once established.

^[1]

The cytokine cascade in more detail. Bacterial colonisation triggers IL-1β and TNF-α release from macrophages and airway epithelium. These cytokines drive neutrophil recruitment via IL-8 and CXCL-1/2/3. Neutrophils release elastase, proteinase-3, myeloperoxidase, and matrix metalloproteinases (MMP-8, MMP-9), which degrade elastin, collagen and proteoglycans. Simultaneously, elastase cleaves Toll-like receptors and opsonins, blunting bacterial clearance and deepening the inflammatory response. This dual action — tissue destruction and immune dysregulation — is what makes the cycle so hard to break.

^[1]

Airway wall changes beyond dilation. Histologically, bronchiectatic airways show loss of elastin and smooth muscle, mucosal oedema, ulceration, squamous metaplasia, and goblet-cell hyperplasia. Bronchial arteries proliferate and become tortuous, predisposing to haemoptysis. The surrounding parenchyma may show fibrosis, atelectasis or emphysema depending on the aetiology.

^[1]

Why Pseudomonas is uniquely damaging. P. aeruginosa forms a biofilm (quorum-sensing-regulated), shifts to a mucoid alginate-producing phenotype under selection pressure, and is intrinsically and acquired-resistant to many antibiotics. Its elastases (LasA/LasB) and proteases intensify the neutrophil response. Once mucoid Pseudomonas is established, eradication is rarely possible — management shifts from cure to suppression.^[2]

Learn the circle and you can derive every treatment — each therapy breaks one step. Airway clearance breaks the retention step; antibiotics cut the infection step; macrolides dampen the neutrophilic inflammation step and jam bacterial quorum-sensing; treating the cause (remove the foreign body, replace immunoglobulin) restores the initial defence step; and surgery excises the most destroyed segment to interrupt the circle in localised disease. Mechanism first, drug second — that is how you answer "why this treatment?" on a viva.^[1]

Inflammatory contrast (the exam question that distinguishes the chronic suppurative lung diseases): bronchiectasis is predominantly neutrophilic, asthma is eosinophilic/type-2, COPD is mixed. There is an increasingly recognised eosinophilic overlap endotype in bronchiectasis (blood eosinophils at least 300/μL) that is responsive to inhaled corticosteroids and — in severe cases — to anti-IL-5 biologics, but routine ICS is not recommended in non-CF bronchiectasis without an asthmatic/eosinophilic overlap.^[1][3]

The bedside — daily sputum, coarse crackles, clubbing

The syndrome is a chronic productive cough with mucopurulent sputum on most days for months or years, punctuated by exacerbations — and one HRCT confirms it. The old clinical definition demanded cough and sputum on most days for at least 2 consecutive years, but HRCT has retired that clock; you no longer wait two years to diagnose.^[12]

The BTS exacerbation definition is a one-line rule worth memorising — deterioration in at least one of three: sputum volume, sputum purulence/consistency, or breathlessness (often with cough, haemoptysis, fever, malaise, pleuritic pain). And the threshold that fires long-term macrolide therapy is 3 or more exacerbations per year — a number you will be asked.^[1]

Physical signs — the cluster a final-prof candidate must elicit in 60 seconds:^[1]

• Coarse inspiratory and/or expiratory crackles — often positional, over the affected segments.
• Wheeze (from airway obstruction/inflammation).
• Digital clubbing — present in up to a third; classic but not universal.
• Hyperinflation and use of accessory muscles in advanced disease.
• Weight loss and cachexia in end-stage disease.
• Cor pulmonale (raised JVP, ankle oedema, loud P2, hepatomegaly) in end-stage disease with pulmonary hypertension.
• Sinusitis and otitis (think PCD/CVID); nasal polyps (think CF or PCD); situs inversus (Kartagener).^[1]

The atypical presentations examiners deliberately probe — each is a missed diagnosis waiting to happen:^[1]

• 'Dry' bronchiectasis — cough with little sputum, often upper-lobe and post-TB or ABPA; missed because the textbook description assumes wet sputum.
• Elderly patient with recurrent 'pneumonia' in the same segment — the same lobe recurring is bronchiectasis or obstruction until proven otherwise; HRCT and bronchoscopy.
• Child with failure to thrive and chronic productive cough — think CF or primary ciliary dyskinesia; sweat chloride, CFTR genetics, ciliary function testing.
• Immunocompromised host — atypical organisms (NTM, fungi, opportunists); lower threshold for bronchoscopy.
• Pregnant woman — stable disease usually tolerates pregnancy, but exacerbations may worsen; cough and dyspnoea can be mistaken for normal pregnancy.
• Diabetic patient — higher risk of Pseudomonas and NTM infection; TB may coexist.
• Patient presenting with nephrotic syndrome — long-standing bronchiectasis can cause secondary AA amyloidosis.
• Asymptomatic patient with incidental HRCT bronchiectasis — found on CT done for another reason; still requires cause work-up and monitoring.
• Patient with persistent 'cough-variant' presentation only — no sputum, normal examination except localised wheeze or crackles; HRCT is revealing.
• Smoker misdiagnosed with COPD — fixed airflow obstruction and cough attributed to smoking; HRCT shows bronchiectasis and changes management.

^[1]

The mimics — what chronic cough and crackles are NOT

A chronic productive cough or recurrent chest infections is not always bronchiectasis, and the HRCT is the arbiter every time. Separate each mimic by its decisive feature — and reach for the scan before you commit to a label.^[1]

Sputum character is a free diagnostic clue — look at the pot, don't just send it:^[1]

• Purulent/mucopurulent — H. influenzae, Pseudomonas, S. pneumoniae.
• Foul-smelling — anaerobes/aspiration.
• Copious watery green — Pseudomonas aeruginosa.
• Blood-streaked — any cause; raises haemoptysis concern.
• Brownish plugs — ABPA (expectorated mucus plugs).

^[1]

The face-off — one discriminator per mimic, and the test that settles it:^[1]

^[1]

When the cough is chronic but the scan is clean — think beyond bronchiectasis. The non-bronchiectasis chronic cough quartet is upper-airway cough syndrome (post-nasal drip), gastro-oesophageal reflux, ACE-inhibitor therapy, and non-asthmatic eosinophilic bronchitis. Purulent sputum, clubbing, localised crackles, and HRCT dilation are the four features that pull the answer back to bronchiectasis.^[1]

The focused round — history, exam, and the admission threshold

Take the history in the order that finds the cause: when it began, what primed it, and what runs in the family. Ask onset of cough and sputum; childhood triggers (pertussis, measles, recurrent infections, failure to thrive); TB exposure and treatment; the PCD cluster (chronic sinusitis, otitis, infertility); the ABPA cluster (allergy, asthma, eggs/aspirin); family history (CF, alpha-1-antitrypsin, PCD); smoking; connective-tissue disease (especially rheumatoid arthritis); immunisation history; and the growth chart in children.^[1]

Examine for the cluster that earns the diagnosis — clubbing is the single most useful sign. Look for clubbing (the hallmark of chronic suppurative lung disease), pallor and cachexia, nasal polyps (CF, PCD), situs inversus (Kartagener), coarse crackles (often positional), wheeze, hyperinflation, cor pulmonale signs, and chronic sinus disease.^[1]

Grade every exacerbation by sputum, fever, breathlessness, and oxygenation — and know the signs that pull the trigger on admission. Score sputum volume, purulence and colour (the Murray–Stockley scale), fever, breathlessness, oxygen saturation, and haemoptysis volume. Admit the moment you see respiratory distress, hypoxia, cyanosis, massive haemoptysis, confusion (type-2 failure), sepsis, or new pneumonic change.^[1]

The bedside severity grid — who stays outpatient, who gets a bed, who goes to HDU:^[1]

^[1]

The Murray–Stockley sputum colour scale is a free, bedside bacterial barometer — the greener the sputum, the heavier the neutrophil load. Use the colour to triage exacerbations and to track antibiotic response; a sputum pot on the end of the bed tells you more than a single CRP.^[1]

HRCT first — the signet-ring sign, then find the cause

Investigations do three jobs in order: confirm the diagnosis on HRCT, define extent and severity, and hunt the underlying cause. The HRCT carries the first two; a structured cause work-up carries the third — and skipping the work-up is the commonest reason a treatable aetiology goes missed.^[1][2]

Confirm the diagnosis — high-resolution CT (HRCT), and the signs you reproduce verbatim:^[1]

• Gold standard and diagnostic. Modern practice is thin-section volumetric CT (typically 1 mm slices) acquired in full inspiration (± expiratory cuts for air-trapping). The sensitivity and specificity of HRCT for bronchiectasis are very high when modern scanners and thin collimation are used.
• HRCT signs (reproduced verbatim):
  • Signet-ring sign — the internal bronchial diameter exceeds the diameter of the accompanying pulmonary artery branch (the pathognomonic sign). Etymology: the dilated bronchus (the ring) lying next to the smaller artery (the stone) mimics a signet ring on its side — the single most-tested imaging fact in the topic.
  • Tram-track lines — thickened, parallel bronchial walls.
  • Lack of normal bronchial tapering — bronchi remain the same calibre as they course peripherally.
  • Varicose or cystic dilations, sometimes with air-fluid levels (cystic/saccular).
  • Mucus plugging and 'tree-in-bud' appearance (small-airway impaction).
• Distribution is itself a clue — upper-lobe (post-TB, CF, ABPA, radiation) vs lower-lobe (idiopathic, PCD, RA, immunodeficiency, aspiration).

^[1]

HRCT pitfall — traction bronchiectasis. In ILD, bronchi may appear dilated because surrounding fibrosis pulls them open. The key distinction is that traction bronchiectasis is accompanied by reticulation, honeycombing or architectural distortion and the patient has restrictive physiology. Management is of the underlying ILD, not airway clearance.

^[1]

When to order the HRCT — any adult with a consistent syndrome. BTS/ERS guidelines recommend HRCT for chronic productive cough, recurrent chest infections, or persistent haemoptysis — especially when examination shows coarse crackles or clubbing. Do not wait for the "two-year" clock; the scan retires it.^[1]

Find the cause — the structured blood and sputum work-up is not optional:^[1]

Every newly diagnosed adult gets a core panel, with extra tests guided by the clinical phenotype — send the lot at diagnosis, not piecemeal over months.^[1]

^[1]

Spirometry grades severity and tracks decline — it never makes the diagnosis. The pattern is usually obstructive (low FEV1 and FEV1/FVC) with partial bronchodilator reversibility that never returns to normal. DLCO is preserved unless emphysema or ILD coexists; severe disease can show a mixed obstructive–restrictive pattern from atelectasis and fibrosis. Serial FEV1 is the number you trend at every visit.^[1]

Exercise and functional testing. The 6-minute walk test is useful for assessing functional capacity and exertional desaturation. A fall in SpO2 of 4% or more with walking, or a walk distance below predicted, indicates significant functional impairment and may prompt oxygen assessment or pulmonary rehabilitation.^[1]

Multidimensional severity scores — BSI vs FACED, reproduced verbatim

Two scores stratify bronchiectasis into mild, moderate, and severe and predict mortality, exacerbations, and hospitalisation — know both, and know that BSI is the more prognostically accurate while FACED is the bedside shortcut (only 5 inputs).^[4][5][10]

Bronchiectasis Severity Index (BSI, Chalmers 2014):^[4]

^[4]

FACED score (Martinez-Garcia 2014):^[5]

^[1]

Total 0–5 — mild (0–2), moderate (3–4), severe (5); predicts 5-year all-cause mortality. FACED is the bedside shortcut but less comprehensive than BSI — it misses prior hospitalisation and exacerbation frequency, so use BSI when the decision matters.^[13]

The rest of the panel — each test earns its place by the question it answers:^[1]

• Bronchoscopy — for suspected foreign body, endobronchial tumour, single-lobe disease, sampling for NTM/fungi in immunocompromised. Bronchoscopy also allows protected-brush sampling, bronchoalveolar lavage for microbiology, and localisation of bleeding in haemoptysis.
• Echocardiogram — to detect pulmonary hypertension / cor pulmonale in advanced disease.
• 6-minute walk test — functional capacity and oxygenation.
• Sputum colour/score (Murray–Stockley purulence scale) and computerised sputum analysis — useful for monitoring.
• CRP / ESR — non-specific inflammatory markers.
• 24-hour sputum culture — preferred for organism identification, sensitivities, and NTM.
• Urinalysis for proteinuria — to detect secondary AA amyloidosis in long-standing disease.
• Nitric oxide measurement — very low nasal nitric oxide supports PCD.^[1]

The two emergencies — massive haemoptysis and the septic exacerbation

^[1]

Two scenarios take a bronchiectasis patient to resus: massive haemoptysis and a severe exacerbation with respiratory failure or sepsis. Both are time-critical, both are recoverable, and both reward the registrar who acts on a pre-rehearsed sequence rather than improvising.^[1]

Severe exacerbation — run ABCDE, and never delay antibiotics for a sputum pot:^[1]

• A/B — controlled oxygen to target SpO2 94–98% (or 88–92% in chronic CO2 retainers, by analogy with COPD).
• C — IV access, bloods (FBC, U&E, CRP), blood cultures if febrile/septic; treat sepsis with the Surviving Sepsis hour-1 bundle if septic.
• Empirical antibiotics started promptly after sputum culture (never delay antibiotics for tests in a septic patient): route and agent by severity and prior microbiology (see Definitive Management). Standard 14-day course.^[1]
• NIV (BiPAP) if persisting hypercapnic type-2 respiratory failure despite medical therapy, by analogy with COPD.
• Physiotherapy to clear secretions as soon as the patient is stable.

Massive haemoptysis — the killer is asphyxiation, not exsanguination, so position first and embolise definitively. A small volume of blood can rapidly flood the airways and cause asphyxia; early airway control and isolation of the bleeding take precedence. Bleeding side down if the site is known, protect the uninvolved lung, secure the airway, bronchial artery embolisation first-line when bleeding persists, surgical resection reserved for failure or selected localised disease.^[21][22][1]

The stepwise algorithm — rehearse it before you need it:^[1]

1. Call for help — anaesthetics, interventional radiology, thoracic surgery.
2. Protect the good lung — if the bleeding site is known, place the patient with the bleeding lung dependent (bleeding side down) to minimise soiling of the uninvolved lung; avoid lying flat.^[23][22]
3. Airway — high-flow oxygen; if the airway is threatened or bleeding is torrential, secure it with a large-bore endotracheal tube and advance the tube to the main bronchus of the good lung, or use a dual-lumen tube if skilled.
4. Breathing/Circulation — large-bore IV access ×2, bloods (FBC, coagulation, cross-match), group-and-save, correct coagulopathy and thrombocytopenia, resuscitate with crystalloid/blood as needed.
5. Localise — rigid or flexible bronchoscopy once the patient is stable enough; identify the bleeding lobe/segment.
6. Definitive control — urgent bronchial artery embolisation is first-line when significant bleeding persists: it is safe and effective and achieves immediate haemostasis in most cases. Surgical resection is reserved for embolisation failure, localised disease, or recurrent life-threatening bleeding despite embolisation.^[24][22]
7. Aftercare — ICU monitoring, watch for recurrent bleeding (bronchial artery collaterals can reconstitute), and plan definitive management of the underlying bronchiectasis once stable.

^[1]

Remember: the commonest fatal mechanism is asphyxiation from blood flooding the uninvolved lung, not exsanguination. Positioning and protecting the good lung are therefore as important as stopping the bleeding.

^[1]

Emergency department disposition — not every exacerbation needs a bed. Admit the patient who is toxic, hypoxaemic, unable to take oral intake, in respiratory failure, bleeding massively, or failing a short observation. The stable patient with mild symptoms and reliable follow-up goes home on a 14-day oral antibiotic course with augmented airway clearance and a safety-net review. Send the sputum before antibiotics if you can — but never delay antibiotics for a septic patient.^[1]

The classic trap — sedative antitussives. Pleuritic pain limits deep breathing and physiotherapy, so simple analgesia helps — but suppressing the cough suppresses clearance of infected secretions and worsens infection. Reach for paracetamol, not codeine; the cough is doing a job you need it to keep doing.^[1]

The four pillars — treat the cause, clear the airway, control infection, prevent

Long-term management is four pillars, and the order is the order you address them. (1) Treat the underlying cause (ABPA, immunodeficiency, foreign body, CF, PCD); (2) airway clearance (physiotherapy plus mucoactive drugs); (3) infection control (14-day acute antibiotics plus long-term suppression for frequent exacerbators); (4) prevention (vaccination, smoking cessation, pulmonary rehabilitation). Pillar 1 is where a treatable cause earns its own specific therapy — never skip the work-up.^[1][2]

Pillar 1 — Treat the underlying cause

A treatable cause found must be treated on its own merits: ABPA (systemic corticosteroid ± itraconazole/voriconazole); immunodeficiency (replacement immunoglobulin for CVID/hypogammaglobulinaemia); foreign body or tumour (remove — bronchiectasis may regress); rheumatoid arthritis (treat the underlying disease); cystic fibrosis (CFTR modulators and CF-centre MDT); primary ciliary dyskinesia (multidisciplinary care).^[1]

Pillar 2 — Airway clearance

Airway clearance is the cornerstone — and no single technique wins for every patient, so individualise and teach it with a physiotherapist. ACBT (active cycle of breathing) and autogenic drainage are first-line for most adults. PEP devices step in when huffing alone is insufficient or coordination is poor; oscillating PEP (Acapella, Flutter) adds vibration for sticky mucus; high-frequency chest-wall oscillation vests serve severe disease, CF, or patients who cannot perform active techniques. Adjuncts include postural drainage (positioning to drain affected lobes) and a pre-treatment bronchodilator. Review technique regularly — adherence is the rate-limiting step.^[1]

Airway clearance in acute exacerbation. During an exacerbation, secretions increase and the patient may be too breathless for vigorous techniques. Start with gentle breathing exercises, thoracic expansion, and small huffs once pain and dyspnoea are controlled. Increase intensity as the patient improves. Early physiotherapy reduces sputum retention and may shorten hospital stay.

^[1]

Mucoactive pharmacotherapy:

^[1]

• Nebulised hypertonic saline (3–7%) — hydrates the periciliary fluid layer, reduces sputum viscosity, improves clearance; often preceded by a bronchodilator (bronchospasm risk). Randomised studies in non-CF bronchiectasis have shown improved lung function and quality of life.^[15][16]
• Inhaled mannitol (Bronchitol) — improves mucociliary clearance and quality of life in selected patients with acceptable tolerability; trial data support symptomatic benefit.^[17][18]
• Recombinant human DNase (dornase alfa) — The classic trap: dornase alfa works in CF, not in non-CF bronchiectasis — the O'Donnell trial showed harm. It is effective in cystic fibrosis but NOT recommended in non-CF bronchiectasis: the O'Donnell randomised trial showed no benefit and possible harm (more exacerbations and greater FEV1 decline). This is one of the most frequently examined facts in the topic.^[14][1]
• Carbocisteine and other oral mucolytics — modest benefit; trial in selected patients.

Pillar 3 — Infection control

Acute exacerbation — pick the antibiotic by severity and prior microbiology, and give a 14-day course (BTS/ERS default):^[1]

^[1]

Antibiotic selection in detail (adults):

^{[1] [1]}

IV-to-oral switch criteria — improving clinically, able to absorb oral antibiotics, falling inflammatory markers, and an oral agent to which the organism is sensitive. The total course should be 14 days for most exacerbations; some clinicians extend to 21 days for severe Pseudomonas or slow responders.

^[1]

Pseudomonas — try to eradicate early, but once it is chronic and mucoid, shift from cure to suppression. In newly isolated Pseudomonas, attempt eradication with oral ciprofloxacin (or IV antipseudomonal therapy). Once chronic colonisation with a mucoid strain is established, eradication is rarely achievable — the goal becomes long-term suppression with inhaled antibiotics.^[1]

Long-term suppressive antibiotic therapy:

^[1]

• Long-term macrolide (azithromycin 250 mg three times weekly or 500 mg three times weekly; or erythromycin) for patients with 3 or more exacerbations per year despite optimised airway clearance. Mechanism is anti-inflammatory and anti-quorum-sensing, not antimicrobial. Before starting: baseline ECG (QTc) and LFTs, and exclude NTM co-infection — everyone forgets that NTM needs multiple positive cultures and that macrolide monotherapy drives macrolide resistance. Landmark trials — BAT (Altenburg, azithromycin, JAMA 2013), BLESS (Serisier, erythromycin, JAMA 2013), EMBRACE (Wong, azithromycin, Lancet 2012) — each showed a significant reduction in exacerbation frequency; gastrointestinal upset is the commonest adverse effect and macrolide resistance emerges commonly on therapy. Monitoring on therapy: repeat ECG if QTc prolonged, watch for hearing impairment, gastrointestinal upset, and hepatotoxicity.^[7][8][9][1]
• Inhaled antibiotic practical points. Inhaled antibiotics are usually reserved for patients with chronic Pseudomonas and frequent exacerbations despite macrolides and physiotherapy. Before starting, document chronic colonisation (typically 2 or more positive cultures at least 3 months apart) and exclude bronchospasm with a supervised first dose preceded by a bronchodilator. Common regimens include nebulised colistimethate 1–2 million units BD, inhaled tobramycin 300 mg BD in alternating months (Barker and Drobnic trials), aztreonam 75 mg TID, and liposomal amikacin 590 mg OD. Drug delivery depends on the nebuliser device; patients need training and adherence support. Side effects include cough, bronchospasm, wheeze, dyspnoea, and (with aminoglycosides) renal toxicity and ototoxicity.^[19][20][1]

Bronchodilators and inhaled corticosteroids — what helps, and the ICS trap

• Long-acting bronchodilators (LABA, LAMA) are used for breathlessness and airflow obstruction; useful in symptomatic patients with reversibility or coexisting COPD/asthma.
• Routine inhaled corticosteroids are NOT recommended in non-CF bronchiectasis without overlap. ICS is reserved for the asthmatic/eosinophilic overlap endotype (blood eosinophils at least 300/μL, wheeze, atopy).^[1][3]

Pillar 4 — Prevention and rehabilitation

• Vaccination — annual influenza, pneumococcal (PCV/PPSV23 per age/risk schedule), COVID-19; reduces infective exacerbations. Ensure household contacts are vaccinated where possible to reduce transmission.
• Smoking cessation — the single most important modifiable factor accelerating decline.
• Pulmonary rehabilitation — improves exercise capacity and quality of life in breathless patients. Programmes include aerobic exercise, strength training, breathing techniques, airway-clearance education, and psychological support. Benefits are similar to those seen in COPD, even though bronchiectasis is less studied.
• Nutrition and weight management — underweight and malnutrition worsen outcomes. Dietary assessment, oral nutritional supplements, and treatment of micronutrient deficiencies (especially vitamin D) are important.
• Bone health — recurrent oral corticosteroid use (especially in ABPA) and chronic inflammation increase osteoporosis risk; consider bone protection with calcium/vitamin D and bisphosphonates when indicated.
• Patient education and written action plan — recognising exacerbations early, when to seek help, and adherence to physiotherapy.
• Travel and altitude — patients with severe disease or chronic hypoxaemia may need oxygen assessment before air travel or high-altitude exposure.

^[1]

Surgery and transplantation

• Surgical resection (lobectomy/segmentectomy) for localised disease failing medical therapy, massive or recurrent haemoptysis (after embolisation failure), or a destroyed lobe; outcomes best when disease is truly localised.
• Lung transplantation for end-stage bilateral disease (especially CF) with respiratory failure.^[1]

The subtypes that change management — name the cause, change the plan

• ABPA-related bronchiectasis — central (proximal), upper-lobe bronchiectasis in an asthmatic, with eosinophilia, elevated total IgE, Aspergillus-specific IgE/IgG, and central bronchiectasis on HRCT. Treatment is systemic corticosteroid (oral prednisolone 0.5 mg/kg/day to start, weaned on clinical response and serial IgE) with itraconazole as a steroid-sparing agent in corticosteroid-dependent disease. ABPA is a treatable cause — diagnose it and the trajectory changes.^[25][1]

^[1]

ABPA diagnostic approach (high-yield overview): ABPA should be suspected in any asthmatic or CF patient with central bronchiectasis, eosinophilia, and high IgE. Under the revised ISHAM-ABPA working group criteria, diagnosis requires a predisposing condition (asthma or CF) or compatible clinico-radiological presentation, obligate demonstration of fungal sensitisation (Aspergillus-specific IgE or positive skin prick test), serum total IgE at least 500 IU/mL, and two of: Aspergillus-specific IgG (or precipitating antibodies), peripheral blood eosinophilia, or radiological opacities consistent with ABPA. HRCT classically shows central/proximal bronchiectasis, mucus plugging (often high attenuation), and upper-lobe predominance; fleeting infiltrates come and go. Staging distinguishes acute disease, remission, exacerbation, corticosteroid-dependent disease, and treatment-refractory/fibrotic (end-stage bronchiectatic) disease. Treatment of acute ABPA begins with oral prednisolone 0.5 mg/kg/day (BTS: initial 2 weeks, then wean guided by clinical response and serial total IgE); itraconazole is recommended as steroid-sparing therapy in corticosteroid-dependent disease and as an alternative in the acute phase. Monitoring relies on total IgE and eosinophil count — a rising IgE often heralds relapse.^{[25][26][27][1]}

^[1]

• Tuberculosis-associated bronchiectasis — post-TB upper-lobe, often 'dry', with mixed organisms; the commonest aetiology in India and other TB-endemic regions.^[11] Cystic-fibrosis bronchiectasis — upper-lobe, Staphylococcus aureus then Burkholderia cepacia complex and Pseudomonas, CFTR modulators (elexacaftor–tezacaftor–ivacaftor in eligible genotypes), dornase alfa is indicated, sweat chloride and CFTR genetics. Distinct management under a CF-centre MDT. CF differs from non-CF bronchiectasis in several key ways: onset in childhood, upper-lobe predominance, pancreatic insufficiency and malabsorption, diabetes, male infertility, nasal polyps, and a specific requirement for CF-centre care. Dornase alfa, CFTR modulators, and higher-calorie nutrition are central to CF management but not to non-CF disease.
• Primary ciliary dyskinesia / Kartagener syndrome — situs inversus totalis + chronic sinusitis + bronchiectasis (Kartagener triad), with neonatal respiratory distress, chronic otitis media, and infertility (immotile/dyskinetic sperm and cilia). Ciliary biopsy / nasal nitric oxide confirms.

PCD diagnostic approach: PCD is a genetically heterogeneous disorder of ciliary ultrastructure and function. Key clinical clues include neonatal respiratory distress (often with unexplained lobar collapse), year-round nasal congestion and rhinorrhoea starting in infancy, chronic otitis media with glue ear, chronic wet cough from early childhood, situs inversus (in roughly 50% of cases — the Kartagener subgroup), and male infertility (reduced sperm motility). Initial screening is with nasal nitric oxide measurement — PCD patients typically have very low levels. Confirmatory testing requires ciliary ultrastructural analysis by transmission electron microscopy (looking for absent outer dynein arms, inner dynein arm defects, radial spoke defects, or microtubular disorganisation) and ciliary beat frequency/pattern analysis by high-speed video microscopy. Genetic testing for known PCD genes is increasingly available and is useful when biopsy is inconclusive. Management is primarily supportive and aggressive: airway clearance, prompt treatment of infections, hearing support, and genetic counselling. Immunodeficiency-related bronchiectasis. CVID is the most important acquired immunodeficiency to identify. Clues include recurrent bacterial sinopulmonary infections, chronic diarrhoea, autoimmune cytopenias, splenomegaly, and granulomatous-lymphocytic interstitial lung disease. Serum immunoglobulins show low IgG and low IgA or IgM; specific antibody responses to pneumococcal vaccine are impaired. Replacement immunoglobulin (IVIG or subcutaneous IgG) reduces infections and can slow or stabilise bronchiectasis. Specific antibody deficiency and IgA deficiency may also predispose; IgA deficiency alone is usually asymptomatic but can be associated with recurrent infections and coeliac disease. HIV causes bronchiectasis through repeated opportunistic infection and should be excluded in at-risk patients.

• Traction bronchiectasis (interstitial lung disease) — airways 'pulled open' by peribronchial fibrosis rather than destroyed by infection; different mechanism, different management (treat the underlying ILD).
• Post-obstructive bronchiectasis — single-lobe disease from foreign body, endobronchial tumour, or external compression; remove the obstruction and the bronchiectasis may improve.
• Aspiration-related bronchiectasis — dependent segments (posterior upper lobes, lower lobes), often with anaerobic organisms; requires swallow assessment, reflux management, and sometimes gastrostomy.
• NTM-associated bronchiectasis — M. avium complex classically produces right middle-lobe and lingula bronchiectasis in older, thin women with minimal cough (the "Lady Windermere syndrome" phenotype). Diagnosis requires multiple positive cultures or one positive culture with compatible CT findings. Management requires prolonged multidrug therapy and specialist input; macrolide monotherapy must be avoided.

^[1]

Complications — and the preventable-harm list

Uncontrolled bronchiectasis runs a predictable downhill course — exacerbations, haemoptysis, respiratory failure, and the long-latency surprise of amyloidosis. Each complication below is either preventable or detectable early; the job is to name the risk before it arrives.^[1]

• Recurrent exacerbations and accelerated FEV1 decline. Each exacerbation drives further inflammation and wall damage; preventing them is a key treatment goal.
• Massive haemoptysis — the life-threatening emergency (above).
• Cor pulmonale and type-2 respiratory failure in end-stage disease.
• Secondary (AA) amyloidosis — long-standing neutrophilic inflammation drives serum-amyloid-A overproduction; presents as nephrotic-range proteinuria (renal failure); consider when a long-standing bronchiectasis patient develops oedema and proteinuria. Renal biopsy shows amyloid deposits derived from serum amyloid A.
• Chronic lung abscess, empyema, pneumothorax — more common in severe cystic disease.
• Metastatic infection — brain abscess (rare but classical in severe disease), septic emboli, and vertebral osteomyelitis.
• Severe impairment of quality of life — fatigue, breathlessness, depression, social isolation, and reduced exercise capacity.
• Osteoporosis, malnutrition, and cardiovascular comorbidity from chronic inflammation and repeated steroid exposure (especially in ABPA).
• Anxiety and depression — common and under-recognised; screening improves holistic care.

^[1]

The classic pitfalls examiners favour — name all ten under the clock:^[1]

• Missing a treatable cause — ABPA, immunodeficiency, foreign body. A systematic cause work-up is mandatory.
• Using dornase alfa in non-CF bronchiectasis — ineffective, potentially harmful (the O'Donnell trial).
• Failing to escalate to long-term macrolide / inhaled antibiotic in frequent exacerbators or chronic Pseudomonas.
• Under-recognising NTM co-infection — multiple positive cultures required; macrolide monotherapy drives resistance.
• Not involving a physiotherapist — airway clearance is the cornerstone, not an add-on.
• Confusing traction bronchiectasis (ILD) with infection-driven bronchiectasis — the management is entirely different.
• Prescribing routine ICS without an asthmatic/eosinophilic overlap — no benefit and potential harm.
• Using short antibiotic courses — the standard exacerbation course is 14 days in bronchiectasis.
• Ignoring sputum colour/volume trends — these are powerful early warning signs of exacerbation.
• Forgetting to protect the good lung in massive haemoptysis — bleeding side down, intubate the good lung if needed.

^[1]

Prognosis and disposition — the score sets both

Prognosis is wildly variable and the BSI is the single best predictor — severe disease means up to 40% mortality at 10 years. Outcomes track BSI/FACED score, Pseudomonas colonisation, exacerbation frequency, FEV1 decline, radiological extent, and comorbidity; the BSI beats FEV1 alone for mortality, exacerbations, and hospitalisation.^[1]

Quality of life tracks exacerbation frequency, sputum volume, and FEV1 — and the validated tools to measure it are the SGRQ and the QoL-B. Hospitalisations and exacerbations are the strongest drivers of impaired quality of life and the key trial endpoints.^[1]

Disposition — three lanes: clinic for the stable, admission for the emergency, tertiary for the severe or rare:^[1]

• Most stable patients are managed in primary care/clinic with a respiratory physiotherapist and a written action plan.
• Admit for severe exacerbation, respiratory failure, sepsis, or massive haemoptysis.
• Tertiary referral for difficult/severe disease, recurrent hospitalisation, suspected rare cause (PCD, immunodeficiency), and transplant assessment in end-stage disease.

^[1]

Key components of a bronchiectasis clinic. A well-functioning clinic includes: (1) a respiratory physician with expertise in bronchiectasis; (2) a specialist respiratory physiotherapist for airway clearance training; (3) a microbiology/laboratory service able to process sputum for bacteria, fungi and NTM; (4) access to bronchoscopy and interventional radiology; (5) links to immunology, rheumatology, CF and PCD specialists; (6) a nurse specialist for education and self-management support; and (7) smoking cessation, nutrition, and pulmonary rehabilitation services. MDT working is central to good outcomes, particularly in severe or complex disease.

^[1]

Referral thresholds. Refer to a respiratory specialist or bronchiectasis clinic when the diagnosis is new or uncertain, the patient has severe disease (BSI ≥5), chronic Pseudomonas colonisation, frequent exacerbations, massive haemoptysis, suspected rare cause, or failure of primary-care management.^[1]

Follow-up and monitoring:

^[1]

• Regular spirometry (FEV1 trends) every 6–12 months in stable patients, more frequently if declining.
• Sputum cultures when stable (at least annually) and at every exacerbation.
• Review of exacerbation frequency, antibiotic use, and hospital admissions.
• Annual influenza vaccination; pneumococcal vaccination per local schedule.
• BSI/FACED recalculation if clinical status changes.
• Quality of life assessment (SGRQ or QoL-B) to guide supportive care.
• Screening for comorbidities: osteoporosis, cardiovascular disease, anxiety/depression, and sleep disturbance.
• Nutrition and bone health review, especially in patients on repeated corticosteroids.

^[1]

Patient explanation. When explaining bronchiectasis to a patient, use plain language: the airways have been stretched and damaged, so they cannot clear mucus properly. Mucus pools, becomes infected, and causes inflammation, which further damages the airways. The goal of treatment is to break this cycle: clear mucus every day (physiotherapy), treat infections promptly (antibiotics), find and treat any underlying cause, and prevent future infections (vaccines, no smoking). Emphasise that bronchiectasis is usually a long-term condition, but with good management most people can lead active lives and keep exacerbations to a minimum.

^[1]

Prognosis counselling. Explain that severity varies widely. Some patients have mild disease with few exacerbations and near-normal life expectancy; others have severe disease with frequent hospitalisations. Severity scores (BSI/FACED), Pseudomonas status, exacerbation frequency, and FEV1 trend help estimate risk. Reassure that modern management — airway clearance, vaccines, targeted antibiotics, and treating the cause — has substantially improved outcomes compared with historical cohorts.

^[1]

Special populations — children, pregnancy, the elderly, and the immunocompromised

• Children — suspect CF / PCD / immunodeficiency early; pursue sweat chloride and CFTR genetics, ciliary function, and immunoglobulins. Weight-based antibiotics; aggressive physiotherapy; MDT at a paediatric respiratory / CF centre. Growth and nutrition are central to management.
• Pregnancy — most women with stable bronchiectasis tolerate pregnancy well; optimise before conception. Azithromycin is generally avoided in the first trimester if possible; avoid aminoglycosides and tetracyclines; adjust antibiotic choice for fetal safety; intensify physiotherapy. Severe disease increases maternal and fetal risks.

^[1]

Special situations in pregnancy:

^[1]

• Physiological changes — increased minute ventilation, reduced functional reserve, and immune adaptation can unmask previously stable bronchiectasis.
• Drugs to avoid or use cautiously — aminoglycosides (ototoxicity/fetal nephrotoxicity), tetracyclines (fetal bone and dental staining), fluoroquinolones (cartilage toxicity in animal models), and high-dose vitamin A analogues. Azithromycin is generally preferred when a macrolide is needed, but avoid if possible in the first trimester.
• Physiotherapy is safe and should be intensified; positional drainage may need modification in late pregnancy.
• Vaccination — influenza and pneumococcal vaccines are safe in pregnancy and should be given.
• Breastfeeding — most beta-lactams and macrolides are compatible; seek specialist advice for fluoroquinolones and aminoglycosides.
• Delivery planning — most patients can have vaginal delivery; epidural analgesia is safe. Supplemental oxygen and early physiotherapy postpartum help prevent atelectasis.
• Elderly — atypical/blunted presentation (often recurrent 'pneumonia' in one segment); comorbidity; aspiration risk; drug interactions and renal dosing; higher risk of macrolide QTc effects and fluoroquinolone tendon injury. In the elderly, consider silent aspiration, medication-induced cough (ACE inhibitors), and occult malignancy as alternative or contributing diagnoses.
• Immunocompromised — broader organism spectrum including NTM, fungi, opportunists; lower threshold for bronchoscopy and microbiological sampling; consider prophylaxis and earlier IV antibiotics.
• Patients with rheumatoid arthritis — RA is the commonest connective-tissue cause; bronchiectasis may predate or follow the arthritis; manage jointly with rheumatology. It is often lower-lobe and may be associated with Sjogren features or bronchiolitis obliterans.
• Post-transplant — immunosuppression increases risk of NTM and fungal bronchiectasis; specialist management required.
• Diabetes mellitus — diabetes predisposes to Pseudomonas and NTM infection; TB may coexist; glycaemic control improves infection outcomes.

^[1]

Guidelines and the trials that built them

Two guideline families frame practice: the BTS 2019 (UK) and the ERS 2017/2025 (European/global) — same four pillars, same thresholds. Know the headline numbers each sets.^[1]

• BTS 2019 (Hill et al.) — the UK standard; structures management around the four pillars + treatable traits, mandates a systematic cause work-up, defines exacerbations, and sets the 14-day antibiotic course and 3-exacerbation threshold for macrolide therapy.^[1]
• ERS 2017 (Polverino et al.) and ERS 2025 (Chalmers et al.) — the European/global standard; same four-pillar framework, explicit thresholds for long-term macrolide and inhaled antibiotic, and structured multidimensional severity assessment.^[2][3]

Landmark trials that built the evidence base:

^{[1] [1]}

• BAT (Altenburg, JAMA 2013) — azithromycin 250 mg daily for 12 months reduced infectious exacerbations in adults with non-CF bronchiectasis and at least 3 exacerbations in the preceding year (median 0 vs 2 exacerbations; HR 0.29); gastrointestinal side effects occurred in 40% and macrolide resistance in 88% of treated patients.^[7]
• BLESS (Serisier, JAMA 2013) — erythromycin ethylsuccinate 400 mg twice daily for 12 months reduced pulmonary exacerbations in patients with 2 or more exacerbations in the preceding year (IRR 0.57), also reducing 24-hour sputum volume and attenuating FEV1 decline, at the cost of increased macrolide-resistant oropharyngeal streptococci.^[9]
• O'Donnell (Chest 1998) — recombinant human DNase in stable idiopathic bronchiectasis was ineffective and potentially harmful, with more pulmonary exacerbations and greater FEV1 decline than placebo.^[14]
• Barker (Am J Respir Crit Care Med 2000) — inhaled tobramycin reduced Pseudomonas sputum density and achieved eradication in 35% of patients at 4 weeks.^[19]
• Kellett (Respir Med 2011) and Nicolson (Respir Med 2012) — nebulised hypertonic saline improved lung function and/or quality of life in non-CF bronchiectasis.^[15][16]
• Bilton (Thorax 2014) — inhaled mannitol improved quality of life in selected non-CF bronchiectasis patients.^[17]

The negative trial that defines practice:

^[1]

• Recombinant human DNase (dornase alfa) is effective in cystic fibrosis but NOT in non-CF bronchiectasis — the O'Donnell randomised trial showed no clinical benefit and a concerning signal toward increased exacerbations and decline. This is a near-guaranteed exam question.^[14][1]

The ERS 2025 update reinforces several practical points:

^[1]

• Treat bronchiectasis as a multidimensional syndrome with four traits: infection, inflammation, impaired mucociliary clearance, and structural disease.
• Airway clearance should be individualised and supervised; no single technique is superior for all patients.
• Long-term macrolides are indicated for ≥3 exacerbations/year or ≥1 hospitalisation/year despite optimal airway clearance.
• Inhaled antibiotics are indicated for chronic Pseudomonas with recurrent exacerbations or severe disease; first dose should be given under medical observation because of bronchospasm risk.
• Inhaled corticosteroids should not be used routinely; reserve for eosinophilic/asthmatic overlap.
• Systematic cause work-up is recommended at diagnosis and when clinical course suggests a new aetiology.

^[1]

Controversies and evolving areas. The optimal duration of antibiotic therapy for exacerbations (14 days is standard, but some advocate shorter courses for milder cases), the role of inhaled antibiotics in non-Pseudomonas disease, the place of anti-IL-5 or anti-IL-5R biologics in eosinophilic overlap, and the use of procalcitonin to guide antibiotic duration are active areas of research. ERS 2025 emphasises personalised therapy guided by microbiology, severity, and treatable traits rather than a one-size-fits-all approach.

^[1]

Regional differences beyond the UK and India:

^[1]

• United States — guidelines are less unified; the ATS/IDSA NTM guidelines and CF Foundation guidelines are often referenced. Inhaled antibiotics and macrolides are used similarly but access varies with insurance.
• Australia/New Zealand — similar to BTS/ERS; strong emphasis on physiotherapy and MDT care; TB is less common than in South Asia.
• Low- and middle-income countries — post-infectious and post-TB aetiology dominate; sputum bacteriology and local antibiograms guide empirical therapy; cost and availability limit macrolide and inhaled-antibiotic use.

^[1]

Exam pearls — the stems examiners reuse, and the one-liners that score

Recognise the stem and you have half the mark — these are the presentations that recur on NEET-PG and INICET:^[1]

• "A 45-year-old woman with chronic productive cough and clubbing" — think bronchiectasis; order HRCT.
• "A child with bronchiectasis, sinusitis and situs inversus" — Kartagener / PCD.
• "Asthmatic with central upper-lobe bronchiectasis and very high IgE" — ABPA.
• "Patient with bronchiectasis improving on DNase" — the trick is that this is CF bronchiectasis, not non-CF.
• "Recurrent pneumonia in the same lobe" — think obstruction or bronchiectasis; bronchoscopy.
• "Elderly thin woman with right middle-lobe bronchiectasis" — NTM / Lady Windermere.

^[1]

Key one-liners — the lines a viva examiner wants to hear, verbatim:

• Cole's vicious circle — impaired clearance → infection → neutrophilic inflammation → wall destruction → dilation → more impaired clearance. Name the four steps.
• Commonest organism in non-CF bronchiectasis = Haemophilus influenzae. Severity organism = Pseudomonas aeruginosa (mucoid, biofilm-forming, accelerates decline).
• Dornase alfa works in CF, not in non-CF bronchiectasis — the O'Donnell trial (no benefit, possible harm). The classic negative-trial question.
• Long-term macrolide = azithromycin; check QTc and LFTs; exclude NTM first. BAT, BLESS, EMBRACE.
• Massive haemoptysis — bleeding side down, protect the good lung, bronchial artery embolisation first-line, surgery last resort.
• Kartagener triad = situs inversus + chronic sinusitis + bronchiectasis (primary ciliary dyskinesia).
• Traction bronchiectasis = ILD — different mechanism (peribronchial fibrosis pulls airways open).
• BTS exacerbation definition: deterioration in at least one of sputum volume, consistency/purulence, or breathlessness. 14-day antibiotic course.
• FACED (5 inputs: FEV1, Age, Chronic colonisation, Extension, Dyspnoea) vs BSI (age, FEV1, prior hospitalisation, exacerbation frequency, colonisation, mMRC, radiology). BSI is more comprehensive and more prognostic.
• ABPA = central/proximal upper-lobe bronchiectasis + asthma + eosinophilia + high IgE + Aspergillus sensitisation; treat with steroids ± itraconazole.
• Clubbing is common (up to a third) in bronchiectasis — a chronic-suppurative-lung-disease sign.
• Secondary amyloidosis (AA) — long-standing neutrophilic inflammation → nephrotic proteinuria.
• Middle-lobe / lingula bronchiectasis — think aspiration, atypical mycobacteria (Lady Windermere), or middle-lobe syndrome.
• Inhaled antibiotics are for chronic Pseudomonas, not first-line for mild non-Pseudomonas disease.
• Airway clearance is the cornerstone, not antibiotics alone.
• The "Lady Windermere syndrome" — classic M. avium complex infection causing right middle-lobe and lingula bronchiectasis in elderly, thin women with minimal cough; named after the fastidious character in Oscar Wilde's play because patients suppress coughing.
• When not to intubate the bleeding lung — in massive haemoptysis, the aim is to intubate and ventilate the good lung, not the bleeding side, to protect the uninvolved lung from drowning in blood.
• The "cough and sputum for 2 years" definition is the older clinical definition; HRCT is now diagnostic.
• Don't treat bronchiectasis like COPD — bronchodilators help symptoms but do not replace airway clearance and infection control.
• Pseudomonas eradication is rarely achievable once chronic — shift from cure to suppression.
• Macrolides are not antibiotics in this context — their benefit is anti-inflammatory and anti-quorum-sensing.
• The differential of haemoptysis includes bronchiectasis, TB, lung cancer, pulmonary embolism, mitral stenosis, and vasculitis. In bronchiectasis, the source is almost always bronchial arteries (systemic circulation, high pressure), which is why embolisation works.

^[1]

Ward-round test — three stems, thirty seconds each

Stem 1 — the woman with twelve years of daily sputum and clubbing (answer)ShowHide

A 54-year-old woman has a chronic productive cough with a cup of yellow-green sputum daily for over a decade, coarse basal crackles, and finger clubbing. Spirometry is mildly obstructive and does not fully reverse. What is the single decisive investigation, and what sign confirms it? Model: The decisive test is a high-resolution CT — the signet-ring sign (the internal bronchial diameter exceeding the accompanying pulmonary artery) is pathognomonic. Send sputum including NTM culture and run the structured cause work-up (immunoglobulins, total IgE with Aspergillus-specific IgE/IgG, alpha-1-antitrypsin). Do not label this COPD — the clubbing and the daily mucopurulent sputum for years point to bronchiectasis, and the HRCT settles it.^[1][12]

Stem 2 — massive haemoptysis on the ward at 3am (answer)ShowHide

A patient with long-standing bronchiectasis coughs up an estimated 300 mL of bright red blood and is saturating 88 percent. What is the first manoeuvre, and what is the definitive treatment? Model: The killer here is asphyxiation, not exsanguination — so position first. If the bleeding side is known, place the patient bleeding side down (bleeding lung dependent) to protect the uninvolved lung, give high-flow oxygen, secure large-bore IV access, cross-match, and correct coagulopathy. If the airway is threatened, intubate and isolate the good lung (large-bore tube advanced to the good-side main bronchus, or a dual-lumen tube if skilled). Definitive treatment is urgent bronchial artery embolisation — first-line when significant bleeding persists, with immediate haemostasis in most cases; surgical resection is reserved for embolisation failure or selected localised disease. Call anaesthetics, interventional radiology, and thoracic surgery now.^{[21][22][23][24][1]}

Stem 3 — the child with situs inversus, sinusitis, and bronchiectasis (answer)ShowHide

An 8-year-old girl has chronic productive cough, recurrent sinusitis, chronic otitis media with glue ear, and dextrocardia on chest X-ray. HRCT shows bronchiectasis. Name the syndrome, the inheritance, and the confirmatory test. Model: This is Kartagener syndrome, the subgroup of primary ciliary dyskinesia (PCD) with situs inversus — the full triad is situs inversus totalis plus chronic sinusitis plus bronchiectasis. It is autosomal recessive. Screen with nasal nitric oxide (very low in PCD), then confirm with ciliary ultrastructural analysis on biopsy by transmission electron microscopy (absent outer dynein arms is the classic defect). Also ask about neonatal respiratory distress and male infertility in the family. Management is aggressive airway clearance and a multidisciplinary PCD team.^[1]

The mantra

The mantra: Find the cause, clear the airway, culture before antibiotics — and never give dornase alfa outside CF.^[1][14]

References27ShowHide

1. [1]Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society Guideline for bronchiectasis in adults Thorax, 2019.PMID 30545985
2. [2]Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis Eur Respir J, 2017.PMID 28889110
3. [3]Chalmers JD, Haworth CS, Flume P, et al. European Respiratory Society clinical practice guideline for the management of adult bronchiectasis Eur Respir J, 2025.PMID 41016738
4. [4]Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study Am J Respir Crit Care Med, 2014.PMID 24328736
5. [5]Martínez-García MÁ, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score Eur Respir J, 2014.PMID 24232697
6. [6]Cole PJ. Inflammation: a two-edged sword--the model of bronchiectasis Eur J Respir Dis Suppl, 1986.PMID 3533593
7. [7]Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial JAMA, 2013.PMID 23532241
8. [8]Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial Lancet, 2012.PMID 22901887
9. [9]Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial JAMA, 2013.PMID 23532242
10. [10]McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts Thorax, 2016.PMID 27516225
11. [11]Dhar R, Singh S, Talwar D, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry Lancet Glob Health, 2019.PMID 31402007
12. [12]Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis (non-CF) Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis Thorax, 2010.PMID 20627931
13. [13]Minov J, Karadzinska-Bislimovska J, Vasilevska K, et al. Assessment of the Non-Cystic Fibrosis Bronchiectasis Severity: The FACED Score vs the Bronchiectasis Severity Index Open Respir Med J, 2015.PMID 25893025
14. [14]O'Donnell AE, Barker AF, Ilowite JS, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group Chest, 1998.PMID 9596315
15. [15]Kellett F, Robert NM Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis Respir Med, 2011.PMID 22018993
16. [16]Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis Respir Med, 2012.PMID 22349069
17. [17]Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial Thorax, 2014.PMID 25246664
18. [18]Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis Chest, 2013.PMID 23429964
19. [19]Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis Am J Respir Crit Care Med, 2000.PMID 10934074
20. [20]Drobnic ME, Suñé P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa Ann Pharmacother, 2005.PMID 15562142
21. [21]Davidson K, Shojaee S. Managing Massive Hemoptysis Chest, 2020.PMID 31374211
22. [22]Ittrich H, Bock C, Kloeckner R, et al. The Diagnosis and Treatment of Hemoptysis Dtsch Arztebl Int, 2017.PMID 28625277
23. [23]Cahill BC, Ingbar DH. Massive hemoptysis. Assessment and management Clin Chest Med, 1994.PMID 8200191
24. [24]Yoon W, Kim JK, Jeong YY, et al. Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a pictorial review Radiographics, 2002.PMID 12432111
25. [25]Agarwal R, Sehgal IS, Muthu V, et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses Eur Respir J, 2024.PMID 38423624
26. [26]Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis N Engl J Med, 2000.PMID 10717010
27. [27]Patterson K, Strek ME. Allergic bronchopulmonary aspergillosis Proc Am Thorac Soc, 2010.PMID 20463254